Background Patients with breast cancer treated with myelosuppressive chemotherapy are at an increased risk of developing febrile neutropenia (FN), a medical emergency characterized by the occurrence of fever during a period of significant
Search Results
Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy
Douglas W. Blayney, Nicole M. Kuderer, Alice Kate Cummings Joyner, John Jarvis, Dominic Nunag, Jasmine Wells, Lan Huang, Ramon Mohanlal, and Gary H. Lyman
Antibacterial Prophylaxis in Patients with Neutropenia
Brahm H. Segal and Alison G. Freifeld
-induced neutropenia: risks, consequences, and new directions for its management . Cancer 2004 ; 100 : 228 – 237 . 2. Lyman GH Morrison VA Dale DC . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP
Prevention, Diagnosis, and Treatment of Invasive Fungal Infections in Patients with Cancer and Neutropenia
Thomas A. Cumbo and Brahm H. Segal
Elser C . Early detection of chronic disseminated Candida infection in leukemia patients with febrile neutropenia: value of computer-assisted serial ultrasound documentation . Ann Hematol 1998 ; 77 : 41 - 45 . 10 Bjerke JW Meyers JD
Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia
William Alegria, Bernard L. Marini, Kevin Sellery Gregg, Dale Lee Bixby, Anthony Perissinotti, and Jerod Nagel
Background The optimal duration of antibiotic therapy for patients with febrile neutropenia (FN) remains unknown. The Infectious Diseases Society of America recommends broad-spectrum intravenous antibiotic therapy until neutrophil count recovery
A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group
Gary H. Lyman and Marek S. Poniewierski
Neutropenia and its complications represent the major dose-limiting toxicities associated with systemic cancer chemotherapy and is associated with considerable morbidity, mortality, and cost. 1 Neutropenic events may result in dose reductions or
BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High–Neutropenia Risk Chemotherapy
Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, and Bernadette Eichelberger
Background Prophylaxis with the recombinant human granulocyte colony-stimulating factors (G-CSFs) filgrastim and pegfilgrastim prevents chemotherapy-induced neutropenia; reduces febrile neutropenia (FN) risk and infection-related and early
Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice
Jeffrey Crawford, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff, and Gary H. Lyman
. Talcott JA Siegel RD Finberg R Goldman L . Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule . J Clin Oncol 1992 ; 148 : 2561 – 2568 . 2. Kuderer NM Dale DC Crawford JC
Real-World Impact of a Decision Support Tool on Colony-Stimulating Factor Use and Chemotherapy-Induced Febrile Neutropenia Among Patients With Breast Cancer
Abiy Agiro, Andrea DeVries, Jennifer Malin, and Michael J. Fisch
Factors recommend febrile neutropenia (FN) prophylaxis using a colony-stimulating factor (CSF) when risk, based on the chemotherapy regimen and patient risk factors, is “high” (>20%). 7 CSF prophylaxis may also be considered based on patient risk factors
Treatment Strategies for Myeloid Growth Factors and Intravenous Iron: When, What, and How?
Jeffrey Crawford and George M. Rodgers
Chemotherapy-induced neutropenia is hazardous for 2 reasons: it produces febrile neutropenia (FN), which may result in life-threatening infections and prolonged hospitalizations, and it can necessitate chemotherapy dose reductions and delays
Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value
Michaela A. Dinan, Bradford R. Hirsch, and Gary H. Lyman
the future by more sophisticated personalization of care and more selective administration of interventions to those who stand to benefit most. Use Case: Colony-Stimulating Factors for the Prevention of Febrile Neutropenia Febrile neutropenia
